Balyasny Asset Management L.P. 13D and 13G filings for Lexeo Therapeutics, Inc. Common Stock:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-05-15 06:23 am Sale | 2026-03-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Balyasny Asset Management L.P. | 7,176,144 9.690% | -45,411 (-0.63%) | Filing |
| 2026-02-17 06:39 am Purchase | 2025-12-31 | 13G | LEXEO THERAPEUTICS INC LXEO | Balyasny Asset Management L.P. | 7,221,555 9.890% | 1,826,834 (+33.86%) | Filing |
| 2025-11-14 06:04 am Sale | 2025-09-30 | 13G | LEXEO THERAPEUTICS INC LXEO | Balyasny Asset Management L.P. | 5,394,721 9.990% | -2,950,930 (-35.36%) | Filing |
| 2025-08-14 06:40 am Purchase | 2025-06-30 | 13G | LEXEO THERAPEUTICS INC LXEO | Balyasny Asset Management L.P. | 8,345,651 9.990% | 8,345,651 (New Position) | Filing |